AMERICAN CLINICAL LABORATORY ASSN for AMERICAN CLINICAL LABORATORY ASSN
What was lobbied
4 issue areas, each in the filer's own words, with who lobbied on it and where.
Medicare/Medicaid MMM
Medicare reimbursement for clinical laboratory services; health care reform law implementation issues including application of the medical device tax to clinical laboratories; closing the in-office ancillary services exception to the Stark Law; the regulation of laboratory developed tests; the coding and pricing of molecular pathology laboratory tests; reimbursement and coding issues related to the Clinical Laboratory Fee Schedule; and reimbursement and coding issues related to the Physician Fee Schedule.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JASON DUBOIS New | — |
| JO ANNE GLISSON New | — |
| JENNIFER BULLARD MADSEN New | — |
| SCOTT VAN BUREN MCGOOHAN New | — |
| ALAN MERTZ New | — |
| FRANCESCA FIERRO O'REILLY New | — |
Health Issues HCR
Medicare reimbursement for clinical laboratory services; health care reform law implementation issues including application of the medical device tax to clinical laboratories; closing the in-office ancillary services exception to the Stark Law; the regulation of laboratory developed tests; the coding and pricing of molecular pathology laboratory tests; reimbursement and coding issues related to the Clinical Laboratory Fee Schedule; and reimbursement and coding issues related to the Physician Fee Schedule.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JASON DUBOIS New | — |
| JO ANNE GLISSON New | — |
| JENNIFER BULLARD MADSEN New | — |
| SCOTT VAN BUREN MCGOOHAN New | — |
| ALAN MERTZ New | — |
| FRANCESCA FIERRO O'REILLY New | — |
Budget/Appropriations BUD
Medicare reimbursement for clinical laboratory services; health care reform law implementation issues including application of the medical device tax to clinical laboratories; closing the in-office ancillary services exception to the Stark Law; the regulation of laboratory developed tests; the coding and pricing of molecular pathology laboratory tests; reimbursement and coding issues related to the Clinical Laboratory Fee Schedule; and reimbursement and coding issues related to the Physician Fee Schedule.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JASON DUBOIS New | — |
| JO ANNE GLISSON New | — |
| JENNIFER BULLARD MADSEN New | — |
| SCOTT VAN BUREN MCGOOHAN New | — |
| ALAN MERTZ New | — |
| FRANCESCA FIERRO O'REILLY New | — |
Medical/Disease Research/Clinical Labs MED
Medicare reimbursement for clinical laboratory services; health care reform law implementation issues including application of the medical device tax to clinical laboratories; closing the in-office ancillary services exception to the Stark Law; the regulation of laboratory developed tests; the coding and pricing of molecular pathology laboratory tests; reimbursement and coding issues related to the Clinical Laboratory Fee Schedule; and reimbursement and coding issues related to the Physician Fee Schedule.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JASON DUBOIS New | — |
| JO ANNE GLISSON New | — |
| JENNIFER BULLARD MADSEN New | — |
| SCOTT VAN BUREN MCGOOHAN New | — |
| ALAN MERTZ New | — |
| FRANCESCA FIERRO O'REILLY New | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.